Correlation between salivary and serum CA15-3 concentrations in patients with breast cancer.

Correlation between salivary and serum CA15-3 concentrations in patients with breast cancer. Mol Clin Oncol. 2020 Aug;13(2):155-161 Authors: Assad DX, Mascarenhas ECP, Normando AGC, Chardin H, Barra GB, Pratesi R, Nóbrega YKM, Acevedo AC, Guerra ENS Abstract The early detection of breast cancer enables the use of less aggressive treatment and increases patient survival. The transmembrane glycoprotein mucin 1, which is also known as cancer antigen 15-3 (CA15-3), is aberrantly glycosylated and overexpressed in a variety of epithelial cancers, and serves a crucial role in the progression of the disease. CA15-3 is currently used as a marker of breast cancer. In the present study, CA15-3 concentrations in saliva and blood of patients with breast cancer were evaluated to test new assays to detect salivary CA15-3 in addition to ELISA and its diagnostic value. To the best of our knowledge, there are no previous reports of the use of chemiluminescence assay (CLIA) and electrochemiluminescence assay (ECLIA) in saliva. Saliva and blood were collected on the same day from patients with breast cancer (n=26) and healthy controls (n=28). For each subject, the level of serum CA15-3 was measured using ECLIA, and the level of salivary CA15-3 was measured using ECLIA, CLIA and enzyme-linked immunosorbent assay (ELISA). ELISA and CLIA were able to detect CA15-3 in saliva; however, ECLIA could not detect salivary CA15-3. There was no significant differe...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research